Merck related stories
All articles and analysis
Future 40: Who’s showing private equity leadership?Who are the young guns showing innovation in the industry? Who has the X factor that marks them as a future leader? Our Future 40 list of the 40 individuals aged under 40 set to shape private equity over the next decade.
Deal Mechanic: CBPE & Rosemont PharmaceuticalsIn its six years as owner of Rosemont Pharmaceuticals, CBPE helped the business to overhaul its manufacturing process, expand its product line and bolster its management team – more than doubling EBITDA in the process.
- Frazier’s More joins Gates Foundation
Healthcare investing veteran Bob More has joined the Gates Foundation to help develop a ‘venture capital initiative’ in support of global health.
- Jordan Company exits medical supplier for $850m
GS Capital Partners and Clayton Dubilier & Rice are teaming up to buy Harrington Holdings from The Jordan Company, which first invested in the company in 2007.
- US charges 14, alleging insider trading on PE deals
An 'insider trading network' allegedly paid cash in exchange for tips on deals backed by Silver Lake, TPG, Hellman & Friedman and Blackstone.
- Merck launches €40m venture fund
The drug conglomerate’s division for pioneering prescription drugs has established Merck Serono Ventures to back emerging biotech companies.
- CD&R exits from VWR(2)
US buyout firm Clayton, Dubilier & Rice sold VWR International yesterday. The firm also revealed yesterday it was entering into its first ever deal partnership with rival buyout firm KKR.
- CD&R exits from VWR
US buyout firm Clayton, Dubilier & Rice sold VWR International yesterday. The firm also revealed yesterday it was entering into its first ever deal partnership with rival buyout firm KKR.
- The impact of biotechnology on modern healthcare and drug development
Peter Reinish, partner at Global Life Science Ventures, argues that biotechnology will play a decisive role in the development of the healthcare sector.
- Biotech bet pays big in Merck exit
Lebanon, New Hampshire-based GlycoFi will be acquired by Merck in an exit coup for the biotech company’s venture backers.